Zhenyu Li

7PUBLICATIONS
26CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 06, 2026
Construction and Validation of a Progression-Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification.

|Oct 22, 2025
Single-cell transcriptomics identifies PDIA4 as a marker of progression and therapeutic vulnerability in multiple myeloma.

Wenjie Yu, Jiamin Zhan, Yanxia Wang

|Aug 28, 2024
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy.

Yuekun Qi, Hujun Li, Kunming Qi

|Apr 20, 2024
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.

Ming Shi, Jiaojiao Wang, Hongming Huang

|Apr 17, 2023
CD86 Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression.

Qianqian Zhang, Ruixue Ma, Huimin Chen

|Mar 07, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.

Jieyun Xia, Hujun Li, Zhiling Yan

Pageof 2

Frequent Collaborators

6 joint publications

Ying Wang

4 joint publications

Jiang Cao

4 joint publications

Wei Chen

2 joint publications

Weiying Gu